Optimizing Insulin Therapy in Type 2 Diabetes: Strategies for Individualized Care - Video-Optimizing Insulin in Type 2 Diabetes

Video Transcription

Video Summary

Debbie Hennon, an advanced practice nurse, and Dr. Rodolfo Galindo, an associate professor of medicine, discuss guidelines for initiating insulin therapy in type 2 diabetes patients. They explain the goals of basal insulin therapy and the American College of Endocrinology guidelines for adding basal insulin based on A1C levels and glucotoxicity. The importance of using continuous glucose monitoring (CGM) to guide insulin therapy and titration is emphasized. They provide recommendations on how to avoid hypoglycemia and incorporate CGM into insulin therapy management. Patient testimonial from Liz Capko shares her experience with starting insulin therapy. A case study demonstrates initiating basal insulin therapy. The presenters address financial barriers and racial disparities in insulin access, offering strategies for improving access. <br /><br />In another video, Clive discusses his financial struggle with insulin treatment. The speaker emphasizes addressing social determinants of health, connecting patients with social workers and financial assistance resources. Suggestions include enrolling in Medicare Part D and considering a fixed ratio combination to reduce copay costs. Full adherence to prescribed medication doses is stressed, with resources shared for healthcare professionals to provide patients. Therapeutic inertia is discussed, emphasizing the need for timely adjustment to therapy. Challenges and barriers faced by clinicians and patients are explored, with personalized therapy based on patient factors advocated. The potential benefits of biosimilar insulins and newer insulin developments, including once-weekly injections, are highlighted.

Keywords

insulin therapy

type 2 diabetes

basal insulin

A1C levels

glucotoxicity

continuous glucose monitoring

hypoglycemia

financial barriers

racial disparities

social determinants of health

Medicare Part D

biosimilar insulins